9
Participants
Start Date
June 30, 2025
Primary Completion Date
October 30, 2028
Study Completion Date
October 30, 2028
INCB177054
INCB177054 will be administered at protocol defined dose.
Retifanlimab
Retifanlimab will be administered at protocol defined dose.
Upmc Cancercenter, Pittsburgh
Carolina Bio Oncology, Huntersville
University of Florida Health Shands Hospital, Gainesville
Cancer and Hematology Centers of Western Michigan-Start Midwest, Grand Rapids
South Texas Accelerated Research Therapeutics, San Antonio
The Angeles Clinic and Research Institute, Los Angeles
Valkyrie Clinical Trials, Panorama City
Providence Cancer Institute Franz Clinic, Portland
Hackensack University Medical Center, Hackensack
Lead Sponsor
Incyte Corporation
INDUSTRY